BBT 301
Alternative Names: BBT-301; CBM-301Latest Information Update: 06 Aug 2024
At a glance
- Originator CellionBioMed
- Class Antifibrotics; Small molecules
- Mechanism of Action Calcium activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 06 Aug 2024 Cellion Biomed plans a phase IIa trial for Idiopathic pulmonary fibrosis in second half of 2024 (Cellion Biomed Pipeline, August 2024)
- 01 Sep 2022 Pharmacodynamics data from preclinical study for Idiopathic pulmonary fibrosis (IPF) was released by Bridge Biotherapeutics
- 08 Mar 2022 Bridge Biotherapeutics and CellionBioMed enter into an option-to-license agreement for BBT 301 for multiple fibrotic diseases including idiopathic pulmonary fibrosis